Clinical trials: Non Small Cell Lung Cancer Stage IIIB
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can…
- Conditions
- Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT06632327
- Testing
- Surgical Procedure, Cisplatin, Carboplatin
- Where
- 415 sites in United States
- Volunteers
- 37 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non Small Cell Lung Cancer
Computer-Generated Quality of Life Assessment Program for Advanced Non-Small Cell Lung Cancer Patients (LUNL2)
In the treatment of advanced cancer, maximizing quality of life (QoL) is a fundamental goal for oncologists and their patients. In order to achieve this goal, some form of systematic and reliable QoL assessment is needed in…
- Trial name
- LUNL2 (NCT01337102)
- Testing
- Physician Receives QoL results, Physician Does not receive the results
- Where
- Canada
- Volunteers
- 103 people
- Sponsor
- University Health Network, Toronto
Carcinoma, Non-Small-Cell Lung
Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression
The study is a prospective, open label, multicenter, single arm Phase II clinical trial, aiming to explore the use of neoadjuvant Toripalimab for clinically stage II-IIIB NSCLC patients with EGFR mutations and PD-L1 positive…
- Trial name
- TOPLINE (NCT06269211)
- Testing
- Toripalimab
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Ruijin Hospital
Non-small Cell Lung Cancer
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
The purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant…
- Trial name
- MDT-BRIDGE (NCT05925530)
- Testing
- Durvalumab
- Where
- 49 sites in United States, Austria and 9 more
- Volunteers
- 142 people
- Sponsor
- AstraZeneca
Lung Cancer
HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598
RATIONALE: Collecting samples of tumor tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00896909
- Testing
- gene expression analysis, mutation analysis, polymerase chain reaction
- Volunteers
- 44 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Non-Small Cell Lung Cancer
Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
This is a Phase II, open-label trial of Taxotere® + ZD1839 in elderly patients with Stage III-b or IV NSCLC who have received no prior chemotherapy for metastatic disease.
- Trial name
- NCT00231465
- Testing
- docetaxel (Taxotere®), ZD1839
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Resectable Stage II-IIIB NSCLC
A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)
In recent years, substantial progress has been made in the development of perioperative immunotherapy for non-small cell lung cancer (NSCLC).
- Trial name
- NCT07108816
- Testing
- Neoadjuvant Sacituzumab tirumotecan + tagitanlimab Followed by adjuvant tagitanlimab
- Volunteers
- 52 people
- Sponsor
- Henan Cancer Hospital
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)
RATIONALE: Because of its success in advanced NSCLC both as a single agent and in combination with other chemotherapeutics, it is reasonable to investigate the efficacy and toxicity of docetaxel as a multimodality regimen in this…
- Trial name
- NCT00664105
- Testing
- Carboplatin, Docetaxel, radiation therapy
- Where
- 15 sites in United States
- Volunteers
- 63 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
This phase II trial studies two questions in patients with stage III NSCLC: 1) does it improve cancer control to add the drug Durvalumab, a type of immunotherapy, earlier in the treatment course; and 2) by intensifying treatment…
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT04372927
- Testing
- Cisplatin, Durvalumab, Etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Washington
Lung Cancer
Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00356941
- Testing
- docetaxel, oxaliplatin, radiation therapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lung Cancer
A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer
A randomized phase III trial of platinum-based chemotherapy alone versus platinum-based chemotherapy followed by maintenance therapy with gefitinib in patients with stage IIIB/IV NSCLC.
- Trial name
- NCT00144066
- Testing
- platinum-based chemotherapy alone (up to six cycles), platinum-based chemotherapy followed by maintenance therapy with gefitinib
- Volunteers
- 600 people
- Sponsor
- West Japan Thoracic Oncology Group
Carcinoma, Non-Small-Cell Lung
Study for Patients With Non Small Cell Lung Cancer (NSCLC)
This is a randomized study to assess the efficacy and safety of chemotherapy with platin compared to chemotherapy without platin.
- Trial name
- NCT00168883
- Testing
- Carboplatin, Paclitaxel, Vinorelbine
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Charite University, Berlin, Germany
Lung Cancer
S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00014196
- Testing
- cisplatin, docetaxel, radiation therapy
- Where
- 97 sites in United States
- Volunteers
- 33 people
- Sponsor
- SWOG Cancer Research Network
Non Small Cell Lung Cancer
Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)
Seventy two patients are being asked to take part in this research study because they have been diagnosed with Stage IIIA or IIIB non-small cell lung cancer (NSCLC).
- Trial name
- NCT01108666
- Testing
- Nelfinavir
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non-Small Cell Lung Cancer (NSCLC)
A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer
The purpose of this study is to determine the dose that the vaccine can be given safely to patients when injected directly into the lung tumor, without any serious side effects.
- Trial name
- VTNSCLC (NCT01574222)
- Testing
- autologous dendritic cell adenovirus CCL21 vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- VA Office of Research and Development
Non Small Cell Lung Cancer
Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
This is a phase I/IIa open, uncontrolled, international, prospective clinical trial, in an out-patient setting, in patients with stage IIIB/IV NSCLC.
- Trial name
- NCT00923312
- Testing
- CV9201
- Where
- 14 sites in Germany, Switzerland
- Volunteers
- 46 people
- Sponsor
- CureVac
Lung Cancer
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00754923
- Testing
- sorafenib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Non-Small Cell Lung Cancer
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with bevacizumab and concomitant paclitaxel and carboplatin therapy in…
- Trial name
- NCT00874107
- Testing
- Imprime PGG® Injection, Bevacizumab, Paclitaxel
- Where
- 10 sites in United States, Germany
- Volunteers
- 90 people
- Sponsor
- HiberCell, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.